pandemic, and now as
vaccines become more widely available, we are reporting on how our local schools, businesses and communities are returning to a more normal
future. There s never been more of a need for the kind of local, independent and unbiased journalism that The Day produces.
Please support our work by subscribing today.
Alzheimer s drug sparks emotional battle as FDA nears deadline on whether to approve
A mental fog descended when Phil Gutis was diagnosed with Alzheimer s. An experimental drug, he says, helped dissipate that fog, but now access to the medication could be imperiled. (Photo for The Washington Post by Rachel Wisniewski)
All eyes on Biogen s Alzheimer s drug as FDA deadline nears - Triangle Business Journal bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
By June 7, the FDA is expected to make one of its most important decisions in years: whether to approve a drug for mild cognitive impairment or early-stage dementia caused by Alzheimer s disease.
The drug aducanumab would be the first new Alzheimer’s treatment since 2003, but it is also the latest example of a controversial medication that is passionately supported by patients and advocacy groups but has been rejected by the FDA’s outside advisers.
All eyes on Biogen s experimental Alzheimer s disease drug aducanumab as FDA decision deadlinenears bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.